BioSpace News Archive

Cimeio Therapeutics, a biotechnology company that is the leader of the field of epitope editing, today announced the acceptance of two abstracts to be presented at the American Society of Hematology meeting in December 2023 in San Diego.

Scholar Rock (NASDAQ: SRRK) today announced new data from its Phase 1 DRAGON proof-of-concept trial of SRK-181, a selective inhibitor of latent TGFβ1 activation being developed with the aim of overcoming resistance to checkpoint inhibitor therapy in patients with advanced cancer.

Hudson Therapeutics, Inc. announced that Janice Marie McCourt has been appointed to co-Chief Executive Officer and a member of the Hudson Board of Directors, effective October 30, 2023.

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that on November 1, 2023, ORIC granted a total of 14,800 non-qualified stock options and 2,480 restricted stock units to one new non-executive employee who began their employment with ORIC in October 2023.

Aridis Pharmaceuticals, Inc. (OTCQB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2023.

SQZ Biotechnologies Company (OTC: SQZB), focused on unlocking the full potential of cell therapies, presented clinical data for three programs focused on the treatment of Human Papillomavirus 16 positive (HB16+) driven cancers at the Society for Immunotherapy of Cancer Annual Meeting 2023.

Replimune Group, Inc., a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, announced updated interim results from ARTACUS, a Phase 1/2 clinical trial evaluating RP1 monotherapy for the treatment of skin cancers in patients who have had solid organ or hematopoietic cell transplants.

Theralink Technologies, Inc. announced that their long-standing, strategic partnership with the Inova Schar Cancer Institute is beginning to deliver promising results by way of assessing the feasibility and impact of the actionable information provided by the Theralink assay into Inova’s Molecular Tumor Board -based treatment decisioning making for cancer patients.

Institute of Biomedical Research Corp. is pleased to provide the following update.

In October, the Services PMI® registered 51.8 percent, 1.8 percentage points lower than September reading of 53.6 percent.